Scientists from the Institut Pasteur have identified a previously unknown mechanism by which the anti-PD-1 antibodies used in immunotherapy treatment for several forms of cancer amplify the immune response beyond the tumor itself. By activating specific FcγR receptors in the lymph nodes, these antibodies promote the recruitment of circulating anti-tumor T cells. The findings open up specific avenues for designing more effective immunotherapies.

Find out more (in French)